Verve Therapeutics Future Growth
Future criteria checks 2/6
Verve Therapeutics's earnings are forecast to decline at 9% per annum while its annual revenue is expected to grow at 25.5% per year. EPS is expected to decline by 2.8% per annum. Return on equity is forecast to be -79.4% in 3 years.
Key information
-9.0%
Earnings growth rate
-2.8%
EPS growth rate
| Biotechs earnings growth | 23.2% |
| Revenue growth rate | 25.5% |
| Future return on equity | -79.4% |
| Analyst coverage | Good |
| Last updated | 29 Apr 2024 |
Recent future growth updates
Recent updates
Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28
Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 17 | -284 | -231 | -220 | 6 |
| 12/31/2025 | 10 | -254 | -229 | -205 | 9 |
| 12/31/2024 | 13 | -226 | -219 | -192 | 10 |
| 12/31/2023 | 12 | -200 | -159 | -150 | N/A |
| 9/30/2023 | 8 | -193 | -154 | -142 | N/A |
| 6/30/2023 | 5 | -192 | -173 | -159 | N/A |
| 3/31/2023 | 3 | -179 | -152 | -138 | N/A |
| 12/31/2022 | 2 | -157 | -136 | -122 | N/A |
| 9/30/2022 | 1 | -148 | -127 | -117 | N/A |
| 6/30/2022 | N/A | -125 | -117 | -110 | N/A |
| 3/31/2022 | N/A | -137 | -102 | -96 | N/A |
| 12/31/2021 | N/A | -120 | -82 | -78 | N/A |
| 9/30/2021 | N/A | -113 | -69 | -65 | N/A |
| 6/30/2021 | N/A | -99 | -54 | -50 | N/A |
| 3/31/2021 | N/A | -53 | -47 | -44 | N/A |
| 12/31/2020 | N/A | -46 | -39 | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VERV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VERV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VERV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VERV's revenue (25.5% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: VERV's revenue (25.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VERV is forecast to be unprofitable in 3 years.